Treatment of phosphate retention: The earlier the better?

Article information

Kidney Res Clin Pract. 2014;33(1):3-8

Publication date (electronic) : 2014 February 03

doi : https://doi.org/10.1016/j.krcp.2013.11.004

Patrick Biggar ¹^,, Samuel K.S. Fung ², Markus Ketteler ¹

¹Klinikum Coburg GmbH, Department of Nephrology, Coburg, Germany

²Princess Margaret Hospital, Kowloon West Cluster Hospital Authority, Kowloon, Hong Kong SAR, China

^⁎Corresponding author at: Kunikum Coberg, Med. Klinik III, Nephrology, Ketschendorfer Stasse 33, 96450 Coberg, Germany. patrick.biggar@t-online.de

Received 2013 July 14; Revised 2013 October 2; Accepted 2013 October 5.

Abstract

Over the last 15 years, our knowledge and understanding of the underlying mechanisms involved in the regulation of calcium and phosphate homeostasis in chronic kidney disease have advanced dramatically. Contrary to general opinion in the 20^th century that moderate hypercalcemia and hyperphosphatemia were acceptable in treating secondary hyperparathyroidism, the calcium and phosphate load is increasingly perceived to be a major trigger of vascular and soft tissue calcification. The current treatment options are discussed in view of historical developments and the expectations of the foreseeable future, focusing on the early treatment of hyperphosphatemia. At present, we lack indisputable evidence that active intervention using currently available drugs is of benefit to patients in chronic kidney disease stages 3 and 4.

Keywords: Calcification; Chronic kidney disease; FGF-23; Hyperphosphatemia; Phosphate binders; Prognosis

Introduction

Renal insufficiency and failure are characterized by multiple and complex disturbances in mineral and bone metabolism. In the past decade, the term chronic kidney disease–mineral and bone disorder (CKD-MBD) was developed to describe a “syndrome” which is not exclusively restricted to bone metabolism. In this context, Block et al [1] showed the relevance of increased serum phosphate levels ≥5.52 mg/dL (1.78 mmol/L). In 1998, in a large retrospective observational study of hemodialysis patients, such a level of hyperphosphatemia was shown to be associated with a significant increase in death from cardiovascular disease [1]. Later, at the turn of the millennium, an intensive discussion started after the introduction of oral phosphate binders which were not based on calcium regarding the adverse potential of calcium loading of the body as a synergistic trigger of morbidity from cardiovascular disease [2], [3], [4]. Since then, both the stigmata of CKD-MBD, hyperphosphatemia and a positive calcium balance, have been accepted as key inductors of the initiation and progression of cardiovascular calcification in CKD.

Historical background

Mortality increases in the early stages of CKD at a creatinine clearance ≤60 mL/min [5], [6]. As we have learnt that vessel calcification is not just a simple passive process of calcium–phosphate precipitation, but is a consequence of modified gene expression with the active induction of phenotype transformation of smooth muscle cells into osteoblasts within the vessel wall [7], [8], attention on this process has increased and concentrated on the basic control and regulatory mechanisms involved [9], [10]. The aim of this research is to reduce the potentially lethal sequelae of disturbed homeostasis in mineral metabolism in CKD [11]. Multiple and recent epidemiological studies have documented associations between ionic and humoral abnormalities on the one side, and morbidity and mortality on the other [12].

It was initially believed that progressive fibrosis of the kidneys with a loss of normal parenchymal tissue was the functional cause of decreasing excretory function (recognizable by reduced urine production and solute clearance). It was also believed that this was the underlying cause of the progressive decrease in incretory capacity which results in reduced levels of endogenous active vitamin D and compensatory increases in parathyroid hormone (PTH) levels to ward off imminent hypocalcemia (Fig. 1).

Figure 1

Classic interpretation of secondary hyperparathyroidism due to loss of renal parenchyma and function. PTH, parathyroid hormone; sHPT, secondary hyperparathyroidism. Note. From “CME sHPT: Pathophysiologie des sekundären Hyperparathyreoidismus”, by Floege and Ketteler, Copyright 2005, Thieme, [in German]. Adapted with permission.

In addition, following the discovery of highly potent, protective hormonal mechanisms which induce an increase in phosphaturia (the so-called phosphatonins) and which thus attenuate the development of hyperphosphatemia, the original concept of an exclusive vitamin D–hypocalcemia perception in the development of CKD-MBD has been modified over the last decade to include a primarily phosphate regulated and regulating paradigm (Fig. 2) [13].

Figure 2

Primary phosphate-based regulative mechanisms. CKD, chronic kidney disease; PTH, parathyroid hormone. Note. From “Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?”, by J.B. Wetmore and L.D. Quales, 2009, Natl Clin Pract Nephrol 5, p. 24. Copyright 2008, Nature Publishing Group. Adapted with permission.

Recently, the COSMOS (Current Management Of Secondary Hyperparathyroidism – a Multicenter Observational Study) study results showed a 22% reduction in all-cause mortality and a 29% reduction in cardiovascular mortality in patients treated with phosphate binders. The open cohort, observational study consisted of 6,797 patients followed prospectively for 3 years in 227 dialysis centers from 20 European countries. Remarkably, the reduction in mortality was also shown in patients treated with calcium-based phosphate binders, whereas more marked reductions were noted in patients treated with combinations of phosphate binders [14].

Phosphate control mechanisms

The discovery of the phosphatonins, including fibroblast growth factor 23 (FGF-23) [15], [16] and Klotho [17] allowed new insights into the pathogenesis of CKD-MBD. FGF-23 consists of 251 amino acids with a molecular weight of 26,000 Da and is produced primarily in osteocytes [18]. As yet, the exact mechanisms which result in its secretion have not been completely elucidated; however, it is generally accepted that increased phosphate loading or hyperphosphatemia directly or indirectly stimulates FGF-23. In addition, calcitriol stimulates the secretion of FGF-23, and FGF-23 is bound into feedback loops which also suppress the secretion of PTH and calcitriol [19], [20], [21].

FGF-23 can be detected via its intact and C-terminal sequences, although, at present, certain differential diagnosis cannot be deduced from the two assay targets. Remarkably, FGF-23 values can increase by a factor of more than 1,000-fold in end-stage renal disease, which can, at least in part, be interpreted as a weakening of the feedback loops and, in the case of C-terminal assays, as cumulation in CKD. The production and sensitivity of the receptor-coactivator Klotho is downregulated in CKD as it is also under the direct negative influence of FGF-23. Furthermore, Klotho expression is partially dependent on calcitriol, which is progressively reduced in CKD [22], [23].

In the presence of Klotho, FGF-23 binds to FGF receptors, utilizing a dimeric receptor complex to induce specific signal transduction. FGF receptors are detectable in most organs; however, the coexpression of Klotho is specific to the kidneys and parathyroid glands [24].

FGF-23 suppresses the expression of the sodium–phosphate (NaPi) cotransporters NaPi-2a and NaPi-2c in the proximal renal tubules and augments phosphate excretion [25], [26]. The original name “Klotho” (derived from Greek mythology) illustrates the high expectations regarding new insights, as decreasing Klotho levels in CKD could possibly explain the premature aging of multiple organ systems. In fact, the discoverer of the Klotho gene describes phosphate as the signaling molecule of aging [27].

Remarkably, Isakova et al [28] were able to show that an increase in FGF-23 is detectable early in the development of CKD, although serum phosphate levels were either low or normal in these stages of CKD. At this point it remains speculative and simultaneously still plausible that the increase in FGF-23 could be interpreted as a protective mechanism against phosphate overload in a scenario of already decreasing renal clearance, although the exact trigger mechanism of this regulatory process remains to be identified.

Calcimimetics reduce not only PTH, but also FGF-23 [29]. Chonchol et al [30] showed, in a double-blind randomized, placebo-controlled study of 404 patients in CKD stages 3 and 4, that treatment with cinacalcet suppressed PTH levels in these patients. However, this positive effect was accompanied by an increase in phosphate levels, which was probably caused by a reduction not only in PTH, but also in FGF-23.

Isolated reduction of FGF-23 results in an increase in serum phosphate. This was shown by Shalhoub et al [31] in a study of rats with CKD which were treated with antibodies specific for FGF-23. Partial normalization of bone parameters, i.e. PTH and calcitriol, and osseus structure were observed; however, a marked increase in serum phosphate, vessel calcification, and mortality were also seen. Thus FGF-23 and PTH, in their roles as phosphatonins, are indispensable in producing an adequate reduction in renal phosphate reabsorption from initially 80–90% to approximately 15% in advanced renal failure [32] and therefore in a reduction in deleterious cardiovascular sequelae of phosphate loading. These results confirm the hypothesis that evolving hyperparathyroidism in the early stages of CKD may have to be regarded primarily as a beneficial, adaptive mechanism supporting the homeostasis of normal serum phosphate levels and loads.

Data presented so far suggest that FGF-23 is the parameter which increases first in CKD-MBD [33]. However, FGF-23 can apparently induce left ventricular hypertrophy and therefore potentially increase cardiovascular risk [34], [35]. Activation of renin-angiotensin-aldosterone system (RAAS) or the induction of inflammation have also been suggested as relevant pathomechanisms [36]. Therefore FGF-23 should not be viewed as an isolated laboratory parameter. Depending on the circumstances, FGF-23 is on one hand physiologically protective, but, on the other hand, pathophysiologically detrimental under extreme conditions [37]. It currently remains obscure whether the interpretation and differentiation of adaption or maladaption is acceptable on the basis of the absolute size of FGF-23 levels or if we can assume a relatively sharp distinction between maintained kidney function and terminal end-stage disease with the obligatory requirement of dialysis.

At present, there is no simple picture of FGF-23 regarding monocausal associations and therapeutic aspects; FGF-23 correlates with the progression of renal failure [38] and numerous studies have identified an independent association between FGF-23 and all-cause or cardiovascular prognosis [39], [40], [41], although the quantitative prognostic power of FGF-23 in manifest end-stage renal failure is inhomogeneous at the moment [42], [43], [44].

Interpretations of early phosphate reduction studies in CKD

Surprisingly, and contrary to the expectation of a reduction in vessel calcification in CKD stages 3b–4 by the attenuation of the phosphate load as a result of treatment with oral phosphate binders, Block et al [45] showed the progression of vasculature calcification in a placebo-controlled, direct comparison of phosphate binders, which was especially associated with calcium-based phosphate binders. Although phosphate excretion in urine was reduced by 22%, levels of PTH and FGF-23 remained substantially unchanged. Although the number of patients was relatively small, with approximately 40 patients in each of the four groups in the study, these results highlight our incomplete understanding of this pathophysiology [46]. This specific cohort did not have overt hyperphosphatemia, but had serum phosphate levels just in the high normal range, showing a reduction from 1.36 mmol/L (4.2 mg/dL) in both the active and placebo groups to 1.26 mmol/L (3.9 mg/dL) with active treatment and 1.32 mmol/L (4.1 mg/dL) for the group treated with a placebo. Furthermore, FGF-23 was not highly stimulated overall (mean 223 RU/mL). However, iPTH was moderately increased [mean approximately 80.4 pg/mL (8.52 pmol/L)].

Differing reductions in FGF-23 while treated with various phosphate binders highlight the complexity of these counter-independent relations, with no significant reduction with calcium-based binders compared with larger reductions in FGF-23 with calcium-free binders in patients on hemodialysis [47], [48]. Furthermore, a study by Hill et al [49] of eight patients in CKD stages 3b and 4 with average phosphate levels of 3.8 mg/dL (1.23 mmol/L) showed a neutral calcium and phosphate balance on an average diet containing approximately 1,000 mg calcium and 1,500 mg phosphate per day. Utilizing calcium carbonate as the phosphate binder, this metabolic study confirmed a small but significant reduction in phosphaturia, while iPTH and FGF-23 remained unchanged. The administration of calcium carbonate lead to a positive calcium balance, while, and again unexpectedly, active intervention did not affect the total phosphate balance.

At present we have insufficient data to recommend a target range for FGF-23. In addition, there is no indication to determine FGF-23 in daily clinical routine. However, it appears plausible to evaluate an FGF-23-guided treatment approach in the future and to favor treatment options which modulate the biological mechanisms physiologically. At the moment, attention should focus on the selection of phosphate binders, the differentiated utilization of calcimimetics and diligent administration of vitamin D or a selective vitamin D analog, accounting for bone status dynamics. The future challenge is the recognition of optimal parameter combinations to further adapt treatment options.

Conclusions and future perspectives

With respect to the question “Treatment of phosphate retention — the earlier the better?” the results of the study of Hill et al [49] possibly suggest that there is no early retention of phosphate. However, a repeat study with a phosphate binder not based on calcium may allow further insights into the mechanisms involved because the calcium content of the phosphate binder may have confounded the results. According to the study of Block et al [45], treatment with phosphate binders alone in the early stages of CKD appears to have no persuasive cardiovascular advantages, but patients at risk should possibly be identified in the future by using FGF-23 ranges, which have not yet been defined.

The validity of these assumptions are supported by the recently published DOPPS (The Dialysis Outcomes and Practice Patterns Study) results [50], showing a 25% lower mortality [hazard ratio (HR) 0.75; 95% confidence interval (CI) 0.68–0.83] in patients prescribed phosphate binders when adjusted for serum phosphate level and other covariates. Further adjustment for nutritional indicators attenuated this association (HR 0.88; 95% CI 0.80–0.97). However, this inverse association was only observed for patients with serum phosphate levels ≥3.5 mg/dL (≥1.13 mmol/L). In the instrumental-variable analysis, the facility percentage of phosphate binder prescription adjusted for case mix was associated positively with a better nutritional status and inversely with mortality (HR for 10% more phosphate binders 0.93; 95% CI 0.89–0.96). Further adjustment for nutritional indicators reduced this association to an HR of 0.95 (95% CI 0.92–0.99), thus showing once again the complexity of interactions between phosphate loading and corporeal handling on one hand, and the often overlooked aspect of nutritional status on the other; this also questions the validity of the COSMOS findings.

We also need to test the parallel (synergistic) administration of NaPi-2b receptor inhibitors [51]. FGF-23 inhibits NaPi-2b receptor activity and thus reduces intestinal phosphate absorption [52], [53]. This option appears attractive as an in vitro analysis of rats has shown that >90% of active phosphate absorption is facilitated by the NaPi-2b transporter [54], which is intestinally upregulated while receiving standard treatment with phosphate binders or strict dietary phosphate restriction [55]. Therefore the regulation of the NaPi-2b transporter plays a significant part in phosphate homeostasis [53].

Excessive calcium supplementation appears to be deleterious with respect to cardiovascular integrity. Indeed, a recently published high quality meta-analysis of 11 randomized studies consisting of 4,622 patients showed a 22% reduction in total mortality for calcium-free versus calcium-based phosphate binders (risk ratio 0.78; 95% CI 0.61–0.98) [56]. Furthermore, direct and specific antagonism of FGF-23 effects in early CKD should be avoided.

In our opinion, the indication for treatment should, for the time being, not be based on a supposed and potentially false assumption of inadequate phosphate retention, but on the presence of visible hyperphosphatemia until the basic interdependent mechanisms in CKD have been elucidated in more detail.

Conflicts of interest

Patrick Biggar has received honoraria for speaking and advisory tasks from AbbVie, Amgen, Sanofi/Genzyme, Ineos Health Care, Fresenius Medical Care, Medice, Hexal, and Takeda. Markus Ketteler has received honoraria for speaking and advisory tasks from AbbVie, Amgen, Fresenius Medical Care, Medice, Mitsubishi, Sanofi, Shire, and Vifor, and has received research funding from AbbVie and Amgen. Samuel K.S. Fung has declared no conflict of interest.

References

1. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K.. Association of serum phosphorus and calcium — phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 311998;:607–617. 9531176.

2. Friedman E.A.. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 12006;:704–709. 17699276.

3. Kovesdy C.P., Mehrotra R., Kalantar-Zadeh K.. Battleground: chronic kidney disorders mineral and bone disease — calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol 32008;:168–173. 18045858.

4. Bushinsky D.A.. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin J Am Soc Nephrol 52010;:S12–S22. 20089498.

5. Tonelli M., Muntner P., Lloyd A., Manns B.J., Klarenbach S., Pannu N., James M.T., Hemmelgarn B.R.. Alberta Kidney Disease Network: Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 3802012;:807–814. 22717317.

6. Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., Coresh J., Gansevoort R.T.. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 3752010;:2073–2081. 20483451.

7. Goodman W.G., London G., Amann K., Block G.A., Giachelli C., Hruska K.A., Ketteler M., Levin A., Massy Z., McCarron D.A., Raggi P., Shanahan C.M., Yorioka N., ; Vascular Calcification Work Group. Vascular calcification in chronic kidney disease. Am J Kidney Dis 432004;:572–579. 14981617.

8. Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M.. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 1092011;:697–711. 21885837.

9. Brown E.M.. Extracellular Ca²⁺ sensing, regulation of parathyroid cell function, and role of Ca²⁺ and other ions as extracellular (first) messengers. Physiol Rev 711991;:371–441. 2006218.

10. Brown E.M., Gamba G., Riccardi D., Lombardi M., Butters R., Kifor O., Sun A., Hediger M.A., Lytton J., Hebert S.C.. Cloning and characterization from bovine parathyroid. Nature 3661993;:575–580. 8255296.

11. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M.. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 152004;:2208–2218. 15284307.

12. Floege J., Kim J., Ireland E., Chazot C., Drueke T., de Francisco A., Kronenberg F., Marcelli D., Passlick-Deetjen J., Schernthaner G., Fouqueray B., Wheeler D.C.. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 262011;:1948–1955. 20466670.

13. Wetmore J.B., Quales L.D.. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Natl Clin Pract Nephrol 52009;:24–33.

14. Cannata-Andía J.B., Fernández-Martín J.L., Locatelli F., London G., Gorriz J.L., Floege J., Ketteler M., Ferreira A., Covic A., Rutkowski B., Memmos D., Bos W.J., Teplan V., Nagy J., Tielemans C., Verbeelen D., Goldsmith D., Kramar R., Martin P.Y., Wüthrich R.P., Pavlovic D., Benedik M., Sánchez J.E., Martínez-Camblor P., Naves-Díaz M., Carrero J.J., Zoccali C.: Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 84:998–1008, 2013

15. Strewler G.J.. FGF23, hypophosphatemia, and rickets: has phosphatonin been found? Proc Natl Acad Sci USA 982001;:5945–5946. 11371627.

16. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., Bianco P., Gehron Robey P.. FGF-23 in fibrous dysplasia of bone and its relation to renal phosphate wasting. J Clin Invest 1122003;:683–692. 12952917.

17. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y.I.. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 3901997;:45–51. 9363890.

18. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., Bianco P., Gehron Robey P.. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 1122003;:683–692. 12952917.

19. Krajisnik T., Björklund P., Marsell R., Ljunggren O., Akerström G., Jonsson K.B., Westin G., Larsson T.E.. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 1952007;:125–131. 17911404.

20. Galitzer H., Ben-Dov I., Lavi-Moshayoff V., Naveh-Many T., Silver J.. Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr Opin Nephrol Hypertens 172008;:363–367. 18660671.

21. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., Quarles L.D.. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 172006;:1305–1315. 16597685.

22. Marsell R., Krajisnik T., Göransson H., Ohlsson C., Ljunggren O., Larsson T.E., Jonsson K.B.. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant 232008;:827–833. 17911089.

23. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., Sugimura K., Kishimoto T., Kinoshita S., Kuroki T., Nabeshima Y.. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2802001;:1015–1020. 11162628.

24. Tohyama O., Imura A., Iwano A., Freund J.N., Henrissat B., Fujimori T., Nabeshima Y.. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2792004;:9777–9784. 14701853.

25. Miyamoto K., Segawa H., Ito M., Kuwahata M.. Physiological regulation of renal sodium-dependent phosphate cotransporters. Jpn J Physiol 542004;:93–102. 15182416.

26. Seiler S., Heine G.H., Fliser D.. Was gibt es neues in der CKD-MBD-Pathogenese? Nephrologe 82013;:13–20.

27. Kuro-o M.. A potential link between phosphate and aging—lessons from Klotho-deficient mice. Mech Ageing Dev 1312010;:270–275. 20197072.

28. Isakova T., Wahl P., Vargas G.S., Gutiérrez O.M., Scialla J., Xie H., Appleby D., Nessel L., Bellovich K., Chen J., Hamm L., Gadegbeku C., Horwitz E., Townsend R.R., Anderson C.A., Lash J.P., Hsu C.Y., Leonard M.B., Wolf M.. Fibroblast growth factor-23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 792011;:1370–1378. 21389978.

29. Komaba H., Koizumi M., Tanaka H., Takahashi H., Sawada K., Kakuta T., Fukagawa M.. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 272012;:1967–1969. 22140124.

30. Chonchol M., Locatelli F., Abboud H.E., Charytan C., de Francisco A.L., Jolly S., Kaplan M., Roger S.D., Sarkar S., Albizem M.B., Mix T.C., Kubo Y., Block G.A.. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 532009;:197–207. 19110359.

31. Shalhoub V., Shatzen E.M., Ward S.C., Davis J., Stevens J., Bi V., Renshaw L., Hawkins N., Wang W., Chen C., Tsai M.M., Cattley R.C., Wronski T.J., Xia X., Li X., Henley C., Eschenberg M., Richards W.G.. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 1222012;:2543–2553. 22728934.

32. Slatopolsky E., Robson A.M., Elkan I., Bricker N.S.. Control of phosphate excretion in uremic man. J Clin Invest 471968;:1865. 5666116.

33. Evenepoel P., Meijers B., Viaene L., Bammens B., Claes K., Kuypers D., Vanderschueren D., Vanrenterghem Y.. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 52010;:1268–1276. 20448073.

34. Heine G.H., Seiler S., Fliser D.. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant 272012;:3072–3081. 22851630.

35. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., Gutiérrez O.M., Aguillon-Prada R., Lincoln J., Hare J.M., Mundel P., Morales A., Scialla J., Fischer M., Soliman E.Z., Chen J., Go A.S., Rosas S.E., Nessel L., Townsend R.R., Feldman H.I. St, John Sutton M., Ojo A., Gadegbeku C., Di Marco G.S., Reuter S., Kentrup D., Tiemann K., Brand M., Hill J.A., Moe O.W., Kuro-O M., Kusek J.W., Keane M.G., Wolf M.. FGF23 induces left ventricular hypertrophy. J Clin Invest 1212011;:4393–4408. 21985788.

36. Kovesdy C.P., Quarles L.D.. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant 282013;:2228–2236. 23625971.

37. Ketteler M., Biggar P.H., Liangos O.. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 282012;:821–825. 23233522.

38. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., Ritz E., Kronenberg F., ; MMKD Study Group, Kuen E., König P., Kraatz G., Mann J.F., Müller G.A., Köhler H., Riegler P.. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 182007;:2600–2608. 17656479.

39. Kendrick J., Cheung A.K., Kaufman J.S., Greene T., Roberts W.L., Smits G., Chonchol M.. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 222011;:1913–1922. 21903574.

40. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H.. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 252010;:3983–3989. 20525642.

41. Taylor E.N., Rimm E.B., Stampfer M.J., Curhan G.C.. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 1612011;:956–962. 21570529.

42. Nakano C., Hamano T., Fujii N., Obi Y., Matsui I., Tomida K., Mikami S., Inoue K., Shimomura A., Nagasawa Y., Okada N., Tsubakihara Y., Rakugi H., Isaka Y.. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 502012;:1266–1274. 22425694.

43. Gutiérrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., Smith K., Lee H., Thadhani R., Jüppner H., Wolf M.. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 3592008;:584–592. 18687639.

44. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., Chazot C.. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 242009;:2792–2796. 19395730.

45. Block G.A., Wheeler D.C., Persky M.S., Kestenbaum B., Ketteler M., Spiegel D.M., Allison M.A., Asplin J., Smits G., Hoofnagle A.N., Kooienga L., Thadhani R., Mannstadt M., Wolf M., Chertow G.M.. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 232012;:1407–1415. 22822075.

46. Drüeke T.B., Massy Z.A.. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol 232012;:1277–1280. 22797178.

47. Koiwa F., Kazama J.J., Tokumoto A., Onoda N., Kato H., Okada T., Nii-Kono T., Fukagawa M., Shigematsu T.. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 92005;:336–339. 16076378.

48. Toida T., Fukudome K., Fujimoto S., Yamada K., Sato Y., Chiyotanda S., Kitamura K.. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol 782012;:216–223. 22874110.

49. Hill K.M., Martin B.R., Wastney M.E., McCabe G.P., Moe S.M., Weaver C.M., Peacock M.. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int 832013;:959–966. 23254903.

50. Lopes A.A., Tong L., Thumma J., Li Y., Fuller D.S., Morgenstern H., Bommer J., Kerr P.G., Tentori F., Akiba T., Gillespie B.W., Robinson B.M., Port F.K., Pisoni R.L.. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 602012;:90–101. 22385781.

51. Takahashi Y., Tanaka A., Nakamura T., Fukuwatari T., Shibata K., Shimada N., Ebihara I., Koide H.. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 652004;:1099–1104. 14871431.

52. Miyamoto K., Ito M., Kuwahata M., Kato S., Segawa H.. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 92005;:331–335. 16076377.

53. Sabbagh Y., O’Brien S.P., Song W., Boulanger J.H., Stockmann A., Arbeeny C., Schiavi S.C.. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 202009;:2348–2358. 19729436.

54. Schiavi S.C., Tang W., Bracken C., O’Brien S.P., Song W., Boulanger J., Ryan S., Phillips L., Liu S., Arbeeny C., Ledbetter S., Sabbagh Y.. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 232012;:1691–1700. 22859851.

55. Giral H., Caldas Y., Sutherland E., Wilson P., Breusegem S., Barry N., Blaine J., Jiang T., Wang X.X., Levi M.. Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol 2972009;:F1466–F1475. 19675183.

56. Jamal S.A., Vandermeer B., Raggi P., Mendelssohn D.C., Chatterley T., Dorgan M., Lok C.E., Fitchett D., Tsuyuki R.T.: Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 382:1268–1277, 2013

Article information Continued

(CC BY-NC-ND, http://creativecommons.org/licenses/by-nc-nd/4.0/) :

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).